Logo Image

From Sequential TKIs to Combination Therapy in Advanced GIST: Current Standards, PEAK Phase 3 Data, and Practical Guidance for the Community Oncologist

Experts featured in this series.

EP. 1: Current GIST Treatment Landscape

ByJason Sicklick, MD, FACS,Mark Agulnik, MD,Michael Heinrich, MD ,Seth M. Pollack, MD,Brian Schulte, MD,Neeta Somaiah, MD
Published: | Updated:

Dr. Jason Sicklick from UC San Diego introduces this OncLive Peer Exchange program addressing the evolving post-third-line GIST landscape, joined by sarcoma experts Dr. Mark Agulnik, Dr. Neeta Somaiah, Dr. Michael Heinrich, Dr. Seth Pollack, and Dr. Brian Schulte. The discussion focuses on the first positive Phase 3 second-line trial in over two decades currently under FDA review.

Experts featured in this series.

EP. 2: FDA-Approved Treatment Sequence and Dosing Strategies in GIST

ByJason Sicklick, MD, FACS,Mark Agulnik, MD,Michael Heinrich, MD ,Seth M. Pollack, MD,Brian Schulte, MD,Neeta Somaiah, MD
Published: | Updated:

Dr. Somaiah outlines the current FDA-approved sequence for advanced KIT-mutant GIST, emphasizing that community oncologists may encounter only handful of patients annually. First-line therapy uses imatinib 400mg daily, escalating to 400mg twice daily for KIT exon 9 mutations based on superior activity data.